Hot Stock Analysis: Trinity Biotech plc (NASDAQ:TRIB)
Shares of Trinity Biotech plc (NASDAQ:TRIB) closed the trading at a price of $5.07 with the positive change of +4.54 percent. In the past session approximately 5,042 shares were exchanged against the average daily trading volume of 33,440 shares. The stock touched to the maximum level of $5.07, and it reached the lower level of $4.90 in past session. The stock’s market capitalization has now valued at $106.108 Million. The stock’s low price in its 52 week is $4.22 per share while $6.54 as the 52 week high price.
Trinity Biotech plc (TRIB) recently reported results for the quarter ended March 31, 2018.
Point-of-Care revenues for 1st QUARTER, 2018 reduced from $4.0m to $3.8m when contrast to 1st QUARTER, 2017, a reduction of 5.8 percent. This was Because of a combination of the impact of lower public health spending on U.S. HIV sales and the normal fluctuation of African HIV orders.
Clinical Laboratory revenues rose from $19.5m to $20.0m, which represents a raise of 2.5 percent contrast to 1st QUARTER 2017. As has been the case in previous quarters, this growth was Because of higher Diabetes and Autoimmunity sales.
Gross profit for 1st QUARTER, 2018 amounted to $10.4m representing a gross margin of 43.8 percent. This was higher than the 42 percent achieved in 1st QUARTER, 2017 and was higher than the gross margin stated in each of the subsequent quarters of 2017.
Research and Development expenses remained flat at $1.3m whilst Selling, General and Administrative (SG&A) fell slightly from $7.0m to $6.9m during the quarter.
Operating profit for the quarter was $1.8m, which is higher than the $1.3m achieved in 1st QUARTER, 2017 and this was attributable to the combination of the higher revenues and improved gross margin.
Financing income for the quarter was marginally higher at $0.2m reflecting higher accessible deposit interest rates. In The Meantime, interest payable, mainly arising on the Company’s exchangeable notes, remained static at $1.2m. A further non-cash expense of $0.3m was recognized in the quarter. This was Because of a loss of $0.1m arising on a raise in the fair value of the embedded derivatives associated with the exchangeable notes plus non-cash interest of $0.2m.
The profit after tax, before non-cash financial expenses, for the quarter was $0.7m and compares favorably to $0.2m for the equivalent period last year. This was primarily Because of the improved operating profit this quarter.
The basic EPS (not including non-cash financial expenses) for the quarter was 3.4 cents versus 1.0 cent in 1st QUARTER, 2017. Unconstrained diluted (earning per share) for the quarter amounted to 7.1 cents, which compares to 5.0 cents in the equivalent quarter in 2017.
Earnings before interest, tax, depreciation, amortization and share option expense for the quarter was $3.3m, contrast with $2.7m in 1st QUARTER, 2017.
Share Buyback
During the quarter, the firm bought back 27,000 shares at an average price of $5.15 and a total value of $0.1m. This brings the total purchased since the starting of the program to over 2.5m shares with a total value of $17.5m.
The stock price is trading downbeat from its 200 days moving average with -1.64 percent and up from 50 days moving average with 6.60 percent. (TRIB) is recorded at 0.19 and the relative strength index of the stock stands 59.21. The company net profit margin is -41.40 percent and gross profit margin is 42.70 percent.
Related Posts :